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Adoptive immunotherapy using gene-modified T cells
redirected against cancer has proven clinical efficacy and
tremendous potential in several medical fields. However,
such personalized medicine faces several challenges in the
complexity associated with the current clinical manufac-
turing methods, which hampers dissemination.
Conventionally, the preparation of autologous gene-
modified T cells comprises many (open) handling steps, is
labor intensive and is not adapted to treat large numbers
of patients or for commercial manufacturing. Moreover,
the cell-manufacturing process requires extensive training
of personnel as well as a dedicated infrastructure, which
restricts these clinical procedures to very few institutions
worldwide. In order to face these challenges, Miltenyi
Biotec has dedicated large efforts to further enable auto-
mation of cell manufacturing by developing a unique cell
processing platform, the CliniMACS® Prodigy, which
enables the automated manufacturing of clinical grade
gene-modified T cells in a closed single-use tubing set.
Starting from leukapheresis or whole blood products,
the automated process enables magnetic labeling and
enrichment of T cells, their subsequent stimulation,
gene-modification with lentiviral vectors, expansion and
final formulation with minimal user interaction. Within
the process a novel stimulatory reagent has been imple-
mented: MACS GMP TransAct™ in combination with
TexMACS GMP Medium. TransAct is a colloidal reagent
developed for polyclonal T cell stimulation that is soluble
and can be removed by washing. The reagent is biode-
gradable, sterile filtered, and suitable for potent T cell
activation, gene-modification, and expansion. Clinically
relevant numbers of functional gene-modified T cells
(>109) have been generated within 10-14 days using the
automated manufacturing process.
The flexibility and ease-of-use associated with this
device and the developed process for clinical scale
production of engineered T cells creates a solution for
the treatment of large patient groups and facilitates
economic commercial-scale manufacturing.
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